Neurovance's Series A - III Round

Neurovance raised a round of funding on March 25, 2015.

Neurovance is a privately held, clinical-stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and related disorders. Neurovance is developing centanafadine (CTN, for…

Articles about Neurovance's Series A - III Round: